Jie Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jie Huang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Yongjun Fang
Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
4 shared publications - Liucheng Rong
Department of Haematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China
3 shared publications Bangchang Cheng
Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
1 shared publication- Chuan He
Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication Enxiu Wang
Nanjing CART Medical Technology Co. Ltd, Nanjing, China
1 shared publicationF. Zhang
Liver Transplantation Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
1 shared publication
Latest Publications
- 16 April 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (5) , 1247-1250
Changes in nutritional status and serum proteins in children with acute lymphoblastic leukemia during induction therapy: a single-centre report from China
Over the past several decades, the 5-year relative survival for childhood acute lymphoblastic leukemia (ALL) has exceeded 90% due to improvements in treatment and support care [1]. Patients with le...
- 16 April 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (5) , 1247-1250
Changes in nutritional status and serum proteins in children with acute lymphoblastic leukemia during induction therapy: a single-centre report from China
Over the past several decades, the 5-year relative survival for childhood acute lymphoblastic leukemia (ALL) has exceeded 90% due to improvements in treatment and support care [1]. Patients with le...
- Open Access
- 26 November 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 8 (22) , 5603-5610
CLAG-M chemotherapy followed by umbilical cord blood stem cell transplantation for primary refractory acute myeloid leukaemia in a child: A case report
The prognosis of paediatric primary refractory/relapsed acute myeloid leukaemia (R/R AML) remains poor. Intensive therapy is typically used as salvage treatment for those with R/R AML. No data are currently available about the use of the CLAG-M protocol as salvage therapy in paediatric patients with R/R AML. An 8-year-old patient was diagnosed with acute myeloid leukaemia by bone marrow morphology and immunophenotype. The patient showed poor response to two cycles of induction therapy with 60% blast cells in the bone marrow after the second induction cycle. The patient achieved complete remission after being treated with the CLAG-M protocol as salvage therapy before undergoing umbilical cord blood stem cell transplantation. Morphological complete remission with haematological recovery has hitherto been maintained over 4 mo. Abnormal gene mutations detected at diagnosis were undetectable after haematopoietic stem cell transplantation. Here we present a paediatric patient with primary refractory acute myeloid leukaemia who was successfully treated with the CLAG-M protocol. Given the positive results of the presented patient, large-scale clinical studies are required to assess the role of the CLAG-M protocol in the salvage treatment of refractory or relapsed AML in childhood.
- 26 November 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 8 (22) , 5603-5610
Open AccessCLAG-M chemotherapy followed by umbilical cord blood stem cell transplantation for primary refractory acute myeloid leukaemia in a child: A case report
The prognosis of paediatric primary refractory/relapsed acute myeloid leukaemia (R/R AML) remains poor. Intensive therapy is typically used as salvage treatment for those with R/R AML. No data are currently available about the use of the CLAG-M protocol as salvage therapy in paediatric patients with R/R AML. An 8-year-old patient was diagnosed with acute myeloid leukaemia by bone marrow morphology and immunophenotype. The patient showed poor response to two cycles of induction therapy with 60% blast cells in the bone marrow after the second induction cycle. The patient achieved complete remission after being treated with the CLAG-M protocol as salvage therapy before undergoing umbilical cord blood stem cell transplantation. Morphological complete remission with haematological recovery has hitherto been maintained over 4 mo. Abnormal gene mutations detected at diagnosis were undetectable after haematopoietic stem cell transplantation. Here we present a paediatric patient with primary refractory acute myeloid leukaemia who was successfully treated with the CLAG-M protocol. Given the positive results of the presented patient, large-scale clinical studies are required to assess the role of the CLAG-M protocol in the salvage treatment of refractory or relapsed AML in childhood.
- 12 October 2020
- Published by Taylor & Francis in Immunotherapy
- Vol. 13 (1) , 5-10
Pseudoprogression of Extramedullary Disease in Relapsed Acute Lymphoblastic Leukemia After CAR T-cell Therapy
Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy have rarely been reported. Materials & methods: A child with relapsed B-ALL was treated with CAR T-cell therapy. Bone marrow morphological examination, minimal residual disease, fusion mutation and radiological evaluation of the EM disease were performed before and after CAR T-cell infusion. Results: Radiological assessment revealed a distinct asymptomatic pseudo progression of EM involvements on day 16 after CAR T-cell infusion. Conclusion: Pseudoprogression of EM disease indicates heterogeneous immune-related patterns of response in patients treated with CAR-T therapy. Such patients should be closely monitored and practical immune-related response criteria should be developed for them.
- 12 October 2020
- Published by Taylor & Francis in Immunotherapy
- Vol. 13 (1) , 5-10
Pseudoprogression of Extramedullary Disease in Relapsed Acute Lymphoblastic Leukemia After CAR T-cell Therapy
Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy have rarely been reported. Materials & methods: A child with relapsed B-ALL was treated with CAR T-cell therapy. Bone marrow morphological examination, minimal residual disease, fusion mutation and radiological evaluation of the EM disease were performed before and after CAR T-cell infusion. Results: Radiological assessment revealed a distinct asymptomatic pseudo progression of EM involvements on day 16 after CAR T-cell infusion. Conclusion: Pseudoprogression of EM disease indicates heterogeneous immune-related patterns of response in patients treated with CAR-T therapy. Such patients should be closely monitored and practical immune-related response criteria should be developed for them.
- Open Access
- 26 October 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 14 (6) , 5325-5333
Daidzein impairs Leydig cell testosterone production and Sertoli cell function in neonatal mouse testes: An in vitro study
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 26 October 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 14 (6) , 5325-5333
Open AccessDaidzein impairs Leydig cell testosterone production and Sertoli cell function in neonatal mouse testes: An in vitro study
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- Open Access
- 29 January 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 7 (4) , 941-947
Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression
Lung cancer ranks as the most common type of cancer in males worldwide. Although great advances have been achieved in chemotherapy and radiotherapy, the long‑term survival rate of lung cancer patients has not improved significantly. Dissemination of lung cancer in the thoracic cavity and metastatic spread to the liver, bone and brain are characteristic of non‑small cell lung cancer (NSCLC), constituting the primary source of morbidity and mortality in lung cancer. Increasing evidence also indicates that the CXC chemokine receptor 4 (CXCR4)/chemokine CXC motif ligand 12 (CXCL12) chemokine axis is important for the cell invasion and migration of lung cancer. CXCR4 is a G protein‑coupled receptor with a major role in lymphocyte homing. Its ligand, CXCL12, is secreted by target organs and functions as a highly efficient chemotactic factor for T cells, monocytes, pre‑B cells, dendritic cells and myeloid bone marrow‑derived cells. In the current study, recombinant CXCR4‑specific small interfering RNA‑pBSilence1.1 plasmids were constructed and transfected into the A549 NSCLC cell line in vitro. Reverse transcription polymerase chain reaction and western blotting revealed that CXCR4 was downregulated in transfected cells compared with control cells. The results of MTT and Transwell migration assays indicated that the specific downregulation of CXCR4 inhibited cell growth, invasiveness and migration. Thus, siRNA targeting of CXCR4 may effectively inhibit the effect of CXCL12/CXCR4 on increasing the metastatic potential of NSCLC.
- 29 January 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 7 (4) , 941-947
Open AccessEffect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression
Lung cancer ranks as the most common type of cancer in males worldwide. Although great advances have been achieved in chemotherapy and radiotherapy, the long‑term survival rate of lung cancer patients has not improved significantly. Dissemination of lung cancer in the thoracic cavity and metastatic spread to the liver, bone and brain are characteristic of non‑small cell lung cancer (NSCLC), constituting the primary source of morbidity and mortality in lung cancer. Increasing evidence also indicates that the CXC chemokine receptor 4 (CXCR4)/chemokine CXC motif ligand 12 (CXCL12) chemokine axis is important for the cell invasion and migration of lung cancer. CXCR4 is a G protein‑coupled receptor with a major role in lymphocyte homing. Its ligand, CXCL12, is secreted by target organs and functions as a highly efficient chemotactic factor for T cells, monocytes, pre‑B cells, dendritic cells and myeloid bone marrow‑derived cells. In the current study, recombinant CXCR4‑specific small interfering RNA‑pBSilence1.1 plasmids were constructed and transfected into the A549 NSCLC cell line in vitro. Reverse transcription polymerase chain reaction and western blotting revealed that CXCR4 was downregulated in transfected cells compared with control cells. The results of MTT and Transwell migration assays indicated that the specific downregulation of CXCR4 inhibited cell growth, invasiveness and migration. Thus, siRNA targeting of CXCR4 may effectively inhibit the effect of CXCL12/CXCR4 on increasing the metastatic potential of NSCLC.
- 21 February 2012
- Published by Wolters Kluwer Health
- Vol. 92 (7) , 452-5
[Preliminary clinical evaluations of panipenem-betamipron in the treatment of hematological malignancy infections].
To evaluate the clinical efficacy and safety of intravenous panipenem-betamipron in the treatment of hematological malignancies infections. From October 2009 to December 2010, a total of 286 hematological malignancy infection patients were recruited into this open-label, perspective and multicenter clinical trial to receive an intravenous daily dose panipenem-betamipron of 0.5 g every 6 or 8 hours for 7 - 14 days. All clinical change and adverse reactions were recorded. The total effective rate of panipenem-betamipron in the treatment of hematological malignancy infections was 86.6% (206/238). The effective rates of septicemia, pulmonary infections, urinary tract infections, digestive canal infections, oral infections and other infections were 68.2% (15/22), 89.3% (100/112), 77.8% (14/18), 100% (22/22), 83.3% (10/12) and 86.5% (45/52) respectively. The overall bacterial eradication rate was 85.07% (57/67) and the rate of adverse reactions 5.9% (17/286). Panipenem-betamipron is both safe and effective in the treatment of hematological malignancy infections.
- 21 February 2012
- Published by Wolters Kluwer Health
- Vol. 92 (7) , 452-5
[Preliminary clinical evaluations of panipenem-betamipron in the treatment of hematological malignancy infections].
To evaluate the clinical efficacy and safety of intravenous panipenem-betamipron in the treatment of hematological malignancies infections. From October 2009 to December 2010, a total of 286 hematological malignancy infection patients were recruited into this open-label, perspective and multicenter clinical trial to receive an intravenous daily dose panipenem-betamipron of 0.5 g every 6 or 8 hours for 7 - 14 days. All clinical change and adverse reactions were recorded. The total effective rate of panipenem-betamipron in the treatment of hematological malignancy infections was 86.6% (206/238). The effective rates of septicemia, pulmonary infections, urinary tract infections, digestive canal infections, oral infections and other infections were 68.2% (15/22), 89.3% (100/112), 77.8% (14/18), 100% (22/22), 83.3% (10/12) and 86.5% (45/52) respectively. The overall bacterial eradication rate was 85.07% (57/67) and the rate of adverse reactions 5.9% (17/286). Panipenem-betamipron is both safe and effective in the treatment of hematological malignancy infections.
- 5 December 2011
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (5) , 947-951
Association of genetic variations inmTORwith risk of childhood acute lymphoblastic leukemia in a Chinese population
The mammalian target of rapamycin (mTOR) is an important protein kinase regulating cell survival and apoptosis. To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 and rs2295080) in a case-control study. We observed that the variant genotype TC of mTOR rs2536 was associated with a significantly decreased risk of childhood ALL (adjusted odds ratio [OR] = 0.67, 95% confidence interval [CI] = 0.46-0.96), and the association was more pronounced in high-risk ALL and T-phenotype ALL groups. Additionally, we found that the combined genotypes TC/CC decreased the risk of ALL only in the high-risk ALL group (adjusted OR = 0.54, 95% CI = 0.32-0.91) and T-phenotype ALL group (adjusted OR = 0.29, 95% CI = 0.10-0.84). These results suggest that the mTOR rs2536 polymorphism is involved in the susceptibility to childhood ALL in a Chinese population.
- 5 December 2011
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (5) , 947-951
Association of genetic variations inmTORwith risk of childhood acute lymphoblastic leukemia in a Chinese population
The mammalian target of rapamycin (mTOR) is an important protein kinase regulating cell survival and apoptosis. To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 and rs2295080) in a case-control study. We observed that the variant genotype TC of mTOR rs2536 was associated with a significantly decreased risk of childhood ALL (adjusted odds ratio [OR] = 0.67, 95% confidence interval [CI] = 0.46-0.96), and the association was more pronounced in high-risk ALL and T-phenotype ALL groups. Additionally, we found that the combined genotypes TC/CC decreased the risk of ALL only in the high-risk ALL group (adjusted OR = 0.54, 95% CI = 0.32-0.91) and T-phenotype ALL group (adjusted OR = 0.29, 95% CI = 0.10-0.84). These results suggest that the mTOR rs2536 polymorphism is involved in the susceptibility to childhood ALL in a Chinese population.
- 1 October 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (8) , 2243-2245
Eighteen living related liver transplants for Wilson's disease: A single-center
- 1 October 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (8) , 2243-2245
Eighteen living related liver transplants for Wilson's disease: A single-center